Revenue segments as reported by the company.

Technology & Analytics Solutions

Research & Development Solutions

Contract Sales & Medical Solutions

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative expenses

Depreciation and amortization

Restructuring costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

IQVIA Hlds

IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions and real-world solutions and services to the firm's life science clients. The Research and Development Solutions segment, which primarily serves biopharmaceutical customers, provides outsourced clinical research and clinical trial related services. The Contract Sales and Medical Solutions segment offers health care provider and patient engagement services to both biopharmaceutical customers and the broader healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

IQVIA reports solid Q4 performance, addresses macro challenges proactively

IQVIA delivered a strong performance in Q4 2022 with revenue growth, operational achievements, and solid financial guidance for 2023, underlining its market position and strategic focus.
While facing challenges from macroeconomic factors, wage inflation, and market conditions, the company is proactively addressing these issues through cost-cutting measures and debt reduction strategies.
By leveraging its strengths in stable operations, record bookings, and financial discipline, IQVIA aims to navigate challenges, capitalize on opportunities, and drive sustainable growth in the future.

IQVIA reports solid Q1 growth amidst industry challenges and opportunities

IQVIA Hlds (IQV) Q1 2023 reflects strong financial performance and operational resilience.
Challenges in backlog burn and industry dynamics are being managed effectively.
Opportunities in M&A activity and demand for real-world evidence drive growth.
Steady guidance for 2023 positions the company well for future success.

IQVIA posts strong Q2 results, eyes growth amid AI investments

IQVIA's Q2 performance reflects solid growth and strategic wins in data and analytics solutions.
While facing challenges in decision delays and economic uncertainties, the company's AI investments and strong R&DS segment offer growth opportunities.
With a focus on leveraging AI across business areas and a vast patient data advantage, IQVIA is well-positioned for future success.

IQVIA reports mixed Q3 results, eyes growth through strategic initiatives

IQVIA's Q3 2023 performance showcased strength in R&DS bookings and revenue growth, while TAS faced challenges from foreign exchange and weak demand. The company aims to drive growth through new contracts, cost reduction initiatives, and strategic pricing adjustments, with a focus on stabilizing performance and pursuing growth opportunities in 2024.

IQVIA reports robust Q4 earnings, eyes growth amid challenges

IQVIA's strong performance in bookings and revenue growth positions it well for future success.
While facing challenges in TAS and pricing negotiations, IQVIA's contract wins and guidance for 2024 show resilience.
Opportunities lie in improving demand for TAS, increasing RFPs, and growth in the data business.
Overall, IQVIA's strategic wins and financial outlook indicate a positive trajectory for the company.

IQVIA reports solid Q1 performance, eyes growth through partnerships

IQVIA delivered a solid performance in Q1 2024, meeting revenue expectations and showcasing growth in bookings and pipeline. The company's strengths lie in technology-enabled solutions, global partnerships, and public health initiatives.
Challenges include cancellations impacting revenue, pricing pressures, and the need to navigate market dynamics. However, IQVIA's opportunities in innovation, partnerships, and market expansion position it well for future growth.
Overall, IQVIA's strategic focus on technology, client engagements, and public health initiatives, amidst challenges in cancellations and pricing pressures, presents a resilient outlook. The company's financial performance and industry leadership are key strengths.
With a proactive approach to challenges and a focus on seizing opportunities, IQVIA remains well-positioned for sustained growth and success in the evolving healthcare landscape. The company's adaptability and strategic initiatives drive confidence in its future prospects.

IQVIA reports robust Q2 earnings, eyes growth amidst market challenges

IQVIA Hlds delivered a strong Q2 performance with revenue and earnings growth, supported by efficient operations and solid financial metrics.
While facing challenges such as pricing pressures and market dynamics, the company remains optimistic about future opportunities and growth potential.
Strategic focus on addressing challenges and seizing opportunities will be key to sustaining performance and maximizing shareholder value in the dynamic healthcare landscape.

IQVIA Hlds reports Q3 growth, faces study delays and pricing challenges

IQVIA Hlds demonstrated solid financial performance in Q3 2024, driven by revenue growth and increased EPS.
While facing challenges like study delays and pricing pressures, the company's strategic strengths and opportunities for growth remain intact.
With a focus on share buybacks and R&DS growth, IQVIA is positioning itself for sustained success in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm's life science clients. The Research and Development Solutions segment provides outsourced clinical research and clinical trial related services. The Contract Sales and Medical Solutions segment offers health care provider and patient engagement services to both biopharmaceutical customers and the healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.

Biogen

Healthpeak Properties

Leslie's

Over halfway through the trading day on Tuesday, and the broad markets have yet to make up their minds.

Tuesday's Top Afternoon Analyst Calls: Peloton, Biogen, Square, Lockheed Martin and More

MORRISVILLE, N.C.--(BUSINESS WIRE)--Q2 Solutions, a leading global clinical trial laboratory services organization, resulting from an IQVIA and Quest Diagnostics joint venture, today announced a partnership with Adaptive Biotechnologies, a pioneer and leader in immune-driven medicine. Q2 Solutions will offer its customers the immunoSEQ® Assay, Adaptive's next-generation sequencing (NGS) based immunosequencing solution, which is used to quantify adaptive immune receptors at high-throughput, leve

Q2 Solutions, an IQVIA and Quest Diagnostics Joint Venture, Teams With Adaptive Biotechnologies to Market immunoSEQ® Assay, the Leading Quantitative Large-Scale Immunosequencing Solution

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a collaboration with Servier, an independent global pharmaceutical company, to reinvent their R&D clinical development processes and support their long-term R&D success. Servier has ambitious plans for growth and is committed to therapeutic progress to serve p

IQVIA and Servier Collaborate to Reinvent Clinical Development

IQVIA Holdings (IQV) stock has been benefiting from consecutive better-than-expected top- and bottom-line performances and encouraging yearly guidance.

IQVIA Holdings (IQV) Stock Up 16.3% in 6 Months: Here's Why

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE: IQV) said today that it is pleased to be a supporter of the Real World Evidence Leadership Forum, a group consisting of senior RWE executives from 18 major pharmaceutical companies. The forum acts as a non-competitive collaboration to understand, discuss and respond to internal and external RWE challenges and opportunities with a single expert voice and the aim of improving outcomes for patients globally. “As the worl

IQVIA Supports Collaborative Forum of Top Pharma Leaders to Advance the Use and Acceptance of Real World Evidence

IQVIA (IQV) reported earnings 30 days ago. What's next for the stock?

IQVIA (IQV) Down 0.1% Since Last Earnings Report: Can It Rebound?

IQVIA Holdings Inc. (IQV) CEO Ari Bousbib on Q3 2020 Results - Earnings Call Transcript

IQVIA's (IQV) third-quarter 2020 revenues and earnings increase year over year.

IQVIA (IQV) Beats on Q3 Earnings & Revenues, Ups 2020 View

IQVIA (IQV) delivered earnings and revenue surprises of 7.95% and 1.29%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

IQVIA Holdings (IQV) Tops Q3 Earnings and Revenue Estimates

Shares of IQVIA Holdings (NYSE:IQV) rose 3% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 1.87% over the past year to $1.63, which beat the estimate of $1.52.

IQVIA Holdings: Q3 Earnings Insights

IQVIA (IQV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IQVIA Holdings (IQV) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

IQVIA Holdings (IQV) Hits a 52-Week High: What's Driving It?

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE: IQV), in scientific partnership with the U.S. Food and Drug Administration, will provide agile analytics from IQVIA’s CARE Project COVID-19 registry to support better understanding of how people in the community are affected by exposure to the coronavirus. IQVIA’s research will show what symptoms individuals experience, the length and severity and whether any medications or vitamin supplements they are taking affect t

IQVIA Joins FDA to Advance COVID-19 Understanding at Community Level through COVID Active Research Experience (CARE) Project

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), will announce its third-quarter financial results before the market opens on Tuesday, October 20, 2020. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the pr

IQVIA to Announce Third-Quarter Results on October 20, 2020

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.

IQVIA’s eCOA Solution Receives 2020 Fierce Innovation Award

IQVIA’s RIM Smart Honored as Gold Stevie® Award Winner in 2020 American Business Awards®

IQVIA (IQV) Down 2.2% Since Last Earnings Report: Can It Rebound?

Consecutive better-than-expected top- and bottom-line performances and encouraging yearly guidance are driving IQVIA Holdings (IQV) stock.

IQVIA Holdings (IQV) Stock Up 2.3% Year to Date: Here's Why

Allovir, Inc.

Xerox

Compass Diversified Holdings

eHealth

F5 Networks

QuidelOrtho Corp

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it.

Notable Insider Buys at Allovir, Xerox And Many More

IQVIA’s Nancy Dreyer and Deepa Desai Honored with 2020 PharmaVOICE Awards

ShotSpotter

IQV vs. SSTI: Which Stock Is the Better Value Option?

IQV vs. SSTI: Which Stock Should Value Investors Buy Now?

IQVIA Launches OCE Optimizer to Help Intelligently Plan HCP Engagements and Maximize Commercial Effectiveness

IQVIA Human Data Science Research Collaborative Initiative Waives Data Access Fees for Academic Researchers

IQVIA Holdings Inc. (IQV) CEO Ari Bousbib on Q2 2020 Results - Earnings Call Transcript

IQVIA's (IQV) second-quarter 2020 revenues and earnings decrease year over year.

News for IQVIA Hlds Stock (IQV)